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Tau hyperphosphorylation is one hallmark of Alzheimer’s disease (AD) pathology. Pharmaceutical
companieshavethusdevelopedkinaseinhibitorsaimingtoreduce tauhyperphosphorylation. Oneobstacle
in screening for tau kinase inhibitors is the low phosphorylation levels of AD-related phospho-epitopes in
normal adult mice and cultured cells. We have shown that hypothermia induces tau hyperphosphorylation
in vitro and in vivo. Here, we hypothesized that hypothermia could be used to assess tau kinase inhibitors
efficacy.Hypothermiaappliedtomodelsofbiologicalgradualcomplexitysuchasneuronal-likecells,exvivo
brain slices and adult non-transgenic mice leads to tau hyperphosphorylation at multiple AD-related
phospho-epitopes. We show that Glycogen Synthase Kinase-3 inhibitors LiCl and AR-A014418, as well as
roscovitine, a cyclin-dependent kinase 5 inhibitor, decrease hypothermia-induced tau
hyperphosphorylation, leading to different tau phosphorylation profiles. Therefore, we propose
hypothermia-inducedhyperphosphorylationasareliable,fast,convenientandinexpensivetooltoscreenfor
tau kinase inhibitors.
A
lzheimer’s disease is a neurological disease marked by progressive neuronal loss, as well as memory
deficits
1. AD is characterized by two specific histological lesions: amyloid plaques, composed of amy-
loid-b peptides deposits
2, and neurofibrillary tangles, composed of hyperphosphorylated and aggregated
protein tau
3,4 Tau hyperphosphorylation can induce tau aggregation in vitro
5, and decrease its solubility in vivo
6.
Tau phosphorylation is a highly regulated process resulting from the balance between kinase and phosphatase
activities
7. During AD development, increased tau phosphorylation is thought to result from a deregulation of
these activities
8. For example, protein phosphatase 2A (PP2A) activity and expression are decreased in AD
brains
9,10. Tau kinases such as GSK-3b
11,12 and Cdk5
13 have also been implicated. Many laboratories and phar-
maceuticalcompanieshavethusfocusedonthedevelopmentofspecificinhibitorsforthesekinases.Forinstance,
GSK-3b inhibitors were shown to reduce tau pathology in a mouse model of neurodegeneration
14, and are
currently in clinical trials
15. One of the main roadblocks for drug screening and testing is that normal adult mice
and cells in culture have low basal tau phosphorylation levels at many AD-related phospho-epitopes. Previously,
we demonstrated that hypothermia induced by either glucose metabolism deregulation
16 or anesthesia
17–19 leads
to tau hyperphosphorylation at multiple epitopes in the mouse brain. Here, we tested the applicability of
hypothermia as a model to screen for specific kinase inhibitors, based on hypothermia’s capability to reliably
inducetauhyperphosphorylation.Asexpected,hypothermicconditionsledtorapidtauhyperphosphorylationat
major phospho-epitopes deregulated in AD in neuroblastoma cells, metabolically active brain slices, as well as in
non-transgenic mice. Treatment in various biological models with known GSK-3 or Cdk5 kinase inhibitors
prevented partially or totally hypothermia-induced tau hyperphosphorylation. Based on these observations,
weproposehypothermiaasareliable,easyandinexpensivemodeltoscreenforandcharacterizepharmacological
modulators of tau phosphorylation.
Results
Anesthesia-inducedtauhyperphosphorylationispartiallypreventedbyLiCladministrationinvivo.Wehave
shown previously that anesthesia-induced hypothermia causes tau hyperphosphorylation in vivo
17. In this study,
we used ketamine/xylazine anesthesia to induce tau hyperphosphorylation. Adult mice were pre-treated for two
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14,20. On the third day,
the mice received a final LiCl injection 75 minutes before anesthesia
(Anes). Rectal temperature analysis showed thatLiCl injection perse
induced a significant drop in body temperature after 15 minutes
(Figure 1A: 37.9uC Ctl1Veh vs 35.6uC Ctl1LiCl, 37.8uC and
Anes1Veh vs 35.8uC Anes1LiCl) and remained constant (,36uC)
until anesthesia. Body temperatures of non-treated mice remained
unchanged until anesthesia (Figure 1A). Anesthesia induced a
progressive and drastic drop in temperature reaching ,26uC after
60 minutes of anesthesia.
As expected, tau phosphorylation significantly increased in
anesthetized animals at all phospho-epitopes analyzed (Figure 1B,
C: Ctl1Veh vs Anes1Veh, AT270:,16x, CP13:,112x;
AT8:,131x; Tau-1:,22.5x, AT180:,16x, MC-6:,13x and
PHF-1:,14x). Treating anesthetized mice with LiCl, but not
vehicle, reduced tau phosphorylation at AT270 (,222%), AT8
(,241%), Tau-1 (,155%) and AT180 (,253%) phospho-epi-
topes (Figure 1B, C: Anes1LiCl vs Anes1 Veh). Other phospho-
epitopes, such as CP13, MC-6 and PHF-1, were also decreased to a
lesser extent in LiCl-treated mice but did not reach statistical signifi-
cance. No significant changes in tau phosphorylation were observed
between control groups (Figure 1B, C: Ctl1Veh vs Ctl1LiCl).
Likewise, no significant changes were observed in total tau levels
in all groups. Notably, GSK-3b serine 9 phosphorylation (pS9),
Figure 1 | Anesthesia-induced tau hyperphosphorylation is prevented by LiCl administration in vivo. A. Mice rectal temperature curve following LiCl
and anesthetic injections. 2-way ANOVA followed by bonferonni’s post test was performed. ***p,0.001 Ctl1LiCl vs Anes1LiCl or Ctl1Veh vs
Anes1Veh,respectively.{{{p,0.001,{{p,0.01,{p,0.05Ctl1VehvsCtl1LiCl.{{{p,0.001,{{p,0.01Anes1VehvsAnes1LiCl.B.Immunoblotsof
corticalhomogenatesextractedproteinusingusingseveralphospho-tauantibodies(AT270,AT8,CP13,Tau-1,pS262andPHF-1).Totaltauwasprobed
using a pan tau antibody. GSK-3b inhibition was monitored by assessing both GSK-3b pS9 levels and total levels of GSK-3b. Actin probe was used as a
loading control. C. Immunoblot quantifications. Ratios of phospho-epitope levels over total tau protein 6SD are represented as a percentage of
vehicle1Anes group condition (checkerboard bar). N53 per condition.
www.nature.com/scientificreports
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anesthetized groups compared to non-anesthetized mice (Figure 1B,
C). A significant increase in GSK-3b pS9 was observed between con-
trol groups (Figure 1B, C: Ctl1Veh vs Ctl1LiCl p,0.001 Bonferroni’s
post hoc test) but not between anesthetized groups (Anes1Veh vs
Anes1LiCl). Taken together, these results demonstrate that anesthe-
sia-induced hypothermia leads to in vivo tau hyperphosphorylation
that can be attenuated by LiCl administration.
Hypothermia-induced tau hyperphosphorylation is prevented
by LiCl treatment in mouse brain slices. As LiCl prevents
hypothermia-induced tau hyperphosphorylation in vivo,w e
intended to transpose these results in an ex vivo model. To this
end, we performed hypothermia experiments using mouse
metabolically active brain slices
21. After 2h under hypothermia, tau
phosphorylation levels were significantly increased at all phospho-
epitopes analyzed, including AT270 (,13x), CP13 (,15x), AT8
(,14x), Tau-1 (,21.5x) and PHF-1 (,12x) (Figure 2A, B: Ctl
37uC vs Ctl30uC). On the other hand, slices exposed to hypothermia
while treated with LiCl for 2h showed reduced tau phosphorylation
levels (CP13:,54%, AT8:,54% and PHF-1:,38% (Figure 2A, B Ctl
30uC vs LiCl 30uC). The same trend was observed on the AT270 and
Tau-1 phospho-epitopes even though it did not reach statistical
significance. AT180 and MC-6 signals were below the detection
Figure 2 | Hypothermia-induced tau hyperphosphorylation is preventedby LiCl treatment inmousebrain slices. Mouse brain sliceswere subjected to
hypothermia for 2h and treated with either LiCl or medium alone. A. Immunoblots of mouse brain slice proteins using several phospho-tau antibodies
(AT270, CP13, AT8 and PHF-1). Total tau was probed using a pan tau antibody. GSK-3b inhibition was monitored by assessing both GSK-3b pS9 levels
and total GSK-3b. B. Immunoblot quantifications. Ratios of phospho-epitope levels over total protein levels 6SD are represented as a percentage of
hypothermic non-treated condition Ctl 30uC (Checkerboard bar). N53 per condition.
www.nature.com/scientificreports
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optimized 20 mM LiCl dose (supplementary Figure S1 online),
which is consistent with previous findings
22. Total tau protein
levels were significantly changed by hypothermia but not by LiCl
treatment. Hypothermia also induced a ,4-fold GSK-3b pS9
increase (Figure 2A, B: Ctl 37uC vs Ctl 30uC), while LiCl treatment
under hypothermic condition raised GSK-3b pS9 levels up to ,8-
fold (Figure 2A, B). Finally, total GSK-3b levels were significantly
increased (,120%) with hypothermia. In summary, and as seen in
vivo, LiCl treatment partially prevented tau hyperphosphorylation
induced by hypothermia in ex vivo brain slices, through GSK-3b
inhibition.
Hypothermia-induced tau hyperphosphorylation is prevented by
LiCltreatmentinwild-typeSH-SY5YcellsorSH-SY5Y3R-tau.To
furthertestourexperimentalparadigminacellsystemmoresuitable
fordrugscreening,weperformedhypothermiaexperimentsinnative
neuroblastoma SH-SY5Y cells from human origin. Cells exposed to
hypothermia(30uC)for2hshowedasignificanttauphosphorylation
increase at PHF-1 (,13x) and Tau-1 (,21.5x) phospho-epitopes
(Figure 3 A, B: Ctl 37uC vs Ctl 30uC). Treating cells with LiCl during
hypothermiareducedtauphosphorylation tocontrollevelsforPHF-
1andTau-1phospho-epitopes(Figure3A,B:Ctl30uCvsLiCl30uC).
Total tau levels were not changed in all groups tested. While no
increase in GSK-3b pS9 was observed in hypothermic cells, this
epitope was increased (,150%) in LiCl treated cells. Other tau
phospho-epitopes, including, AT8, AT180, CP13 and AT270, were
also assessed but were below detection limits, probably because of
low endogenous tau expression and low physiological levels of these
phospho-epitopes in these cells.
To overcome these detection limitations, we performed similar
experiments in SH-SY5Y cells stably expressing human 3R-tau
without any mutation (SH-SY5Y 3R-tau). Here, hypothermic
cells exhibited hyperphosphorylation at several phospho-
epitopes (AT270:,12x, CP13:,14x, AT8:,16x, Tau-1:,22x,
AT180:,12x, MC-6:,115x and PHF-1:,12.5x (Figure 4 A, B:
Ctl 37uCv sC t l3 0 uC). As seen previously, LiCl treatment restored
tau phosphorylation to control levels at AT270, CP13, AT8, Tau-
1, AT180, MC-6 and PHF-1 phospho-epitopes (Figure 4A, B: Ctl
30uC vs LiCl 30uC). Again, total tau protein levels were not affec-
ted in these experimental conditions. Finally, while an increase in
GSK-3b pS9 was observed in hypothermic cells with or without
LiCl treatment, this effect did not reach statistical significance. In
sum, these results show that GSK-3 inhibition by LiCl leads to
reduced hypothermia-induced tau hyperphosphorylation in these
cells.
Hypothermia-induced tau hyperphosphorylation is differentially
prevented by Cdk5 and GSK-3b inhibitors treatment in SH-SY5Y
3R-tau. To extend our experimental paradigm to other kinase
inhibitors, we performed hypothermia experiments using SH-
SY5Y 3R-tau cells treated with the GSK-3b inhibitor AR-A014418
(AR) or the Cdk5 inhibitor roscovitine. Two hours of AR treatment
caused a significant decrease of phosphorylation at Tau-1, AT180,
MC-6 and PHF-1 phospho-epitopes (157%, 262%, 295% and
270% respectively) (Figure 5A, B: AR 30uC vs Ctl 30uC). Tau
phosphorylation was also decreased to a lesser extent at CP13
Figure 3 | Hypothermia-induced tau hyperphosphorylation is prevented by LiCl treatment in natives SH-SY5Y cells. Natives SH-SY5Y cells were
subjected to 2h of hypothermia and treated with either LiCl or medium alone. A. Immunoblots of cell extracted proteins using phospho-tau antibodies
Tau-1andPHF-1.Totaltauwasprobedusingapantauantibody.GSK-3binhibitionwasassessedbymonitoringbothGSK-3bpS9levelsandtotallevels.
B. Immunoblot quantifications. Ratios of phospho-epitope levels over total protein levels 6SD are represented as a percentage of hypothermic
non-treated condition Ctl 30uC (Checkerboard bar). N56 per condition.
www.nature.com/scientificreports
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and AT8 phosphorylation were not decreased by AR treatment
with an unexplained slight significant increase of phosphorylation
at AT270 phospho-epitope. Cells treated with roscovitine showed
significant decreased tau phosphorylation levels at AT180 (252%)
and MC-6 (292%) phospho-epitopes when compared to untreated
conditions (Figure 5A, B: Rscv 30uC vs Ctl 30uC). Notably,
roscovitine had no significant effect at AT270, CP13, AT8, Tau-1
and PHF-1 phospho-epitopes. Total tau protein levels remained
constant in all experimental conditions. In summary, treatments
with Cdk5 inhibitor roscovitine and GSK-3b inhibitor AR-
A014418 leads to different reduced tau phosphorylation patterns
reflecting the specificity of inhibitors used.
Discussion
Here, we used hypothermia to induce tau hyperphosphorylation in
various biological models ranging from immortal cultured cells, to
mice and ex vivo metabolically active slices, to test the effects of tau
kinase inhibitors. We used the GSK-3 inhibitor LiCl as a proof of
concept to demonstrate the feasibility of this approach. As expected,
hypothermiainduced tauphosphorylation at multiple epitopes in all
our models, and treatment with LiCl reduced hypothermia-induced
tau hyperphosphorylation. We also extended this study to two other
kinase inhibitors, AR-A014418 and roscovitine targeting GSK-3 or
Cdk5, respectively, and were able to observe a specific pattern of tau
phosphorylation reduction indicative of kinase inhibitor specificity.
All general anesthetics induce hypothermia through the deregula-
tionofbothnon-shiveringandshiveringthermogenesisregulation
23.
ThishypothermiadirectlyresultsinaninvivoincreaseofAD-related
tau phospho-epitopes including AT270 (Thr181), Tau-1 (Ser195/
Ser198/Ser199/Ser202), Ser199, CP13 (Ser202), AT8 (Ser202/
Thr205), TG-3 (Thr231 conformational), MC-6 (Ser235), Ser262,
PHF-1 (Ser396/Ser404) and Ser422
17,24 at comparable levels to those
observed in AD brains
18; reviewed in
25. This hypothermia-induced
tau hyperphosphorylation is also reversible since we demonstrated
earlierthattauphosphorylationlevelsrecovertonormalafter1week
of post-anesthesia recovery
19. In the present work, we confirmed
these results and showed that ketamine/xylazine led to an hypother-
mia-induced increase of tau phosphorylation from ,1.5x to ,31x,
dependingofthephospho-epitope.Amongallthephospho-epitopes
studied here, Thr231 and Ser262 are accepted to be early tau mod-
ifications in neurodegeneration while other tau phosphorylation
sites such as Thr181, Ser202/Thr205 and Ser396/Ser404 appear later
during disease progression
26. Thr231 and Thr181 are used as AD
biomarkers
27,28, and Ser202/Thr205 is used to stage AD pathology
29.
Thus, the profiles and levels of tau hyperphosphorylation generated
by our hypothermia models are highly relevant to tau pathology
observed in AD.
The exact mechanisms underlying tau hyperphosphorylation in
AD are not well understood. However, it is commonly accepted that
tau hyperphosphorylation results from the imbalance between
kinase and phosphatase activities
8. Among all the phosphatases,
PP2A is the major enzyme that dephosphorylates tau
30, accounting
Figure 4 | Hypothermia-induced tau hyperphosphorylation is prevented by LiCl treatment in SH-SY5Y 3R-tau. SH-SY5Y 3R-tau were subjected to
hypothermia for 2h and treated with either LiCl or medium alone. A. Immunoblots of cell extracted proteins using several phospho-tau antibodies
(AT270,CP13,AT8 Tau-1andPHF-1).Totaltauwasprobed usingapantauantibody.GSK-3binhibitionwasmonitored byassessingbothGSK-3bpS9
levels and total levels. B. Immunoblot quantifications. Ratios of phospho-epitope levels over total protein levels 6SD are represented as a percentage of
hypothermic non-treated condition Ctl 30uC (Checkerboard bar). N53 per condition.
www.nature.com/scientificreports
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regulatingnearlyalltauphosphorylationsites
31.Moreover,itsinhibi-
tion is associated with AD evolution
32. Indeed, both PP2A ex-
pression
10,33 and activity
9,34 are decreased in AD brains. Tau phos-
phorylationisexquisitelysensitivetotemperature,increasingby80%
for each degree below 37uC, due to exponential decrease in PP2A
activity during direct hypothermia
16, or anesthesia-induced hypo-
thermia
17. Therefore, the hypothermia-mediated inhibition of
PP2A is a highly relevant model to study modulators of tau phos-
phorylation targeting tau pathology in AD.
Among tau kinases, GSK-3b
12,35 and Cdk5
36 are considered to be
themaintaukinasesinducingtauhyperphosphorylationinAD.This
statement does not conflict with the aforementioned role of PP2A
inhibition in tau hyperphosphorylation, because phosphatases
merely remove phosphate from tau while kinases are still needed
for hyperphosphorylation to take place. In fact, PP2A inhibition is
considered to be the functional equivalent of activating all the tau
kinases together because PP2A dephosphorylates all known tau epi-
topes while each kinase is specific for only a set of given sites
37. For
example, GSK-3b has been shown in vitro and/or in vivo to target
phosphorylationatsitessuchasThr181,Ser202/Thr205,Thr231and
Ser396/Ser404.Ontheotherhand,Cdk5canphosphorylateabout10
phosphorylation sites in vitro including Ser202, Thr231, Ser235,
Ser396/Ser404
7.
In all our biological systems, we observed that LiCl reduced hypo-
thermia-induced tau hyperphosphorylation at almost every epitope
analyzed. We also observed that the effects of LiCl was more pro-
nouncedincellculturethaninexvivoandinvivomodels.Thiscould
be attributed, in part, to a lower bio-availability of compounds and
for the low phosphorylation of some epitopes such as AT180 and
MC-6 in ex vivo and in vivo models compared to cell cultures.
Essentially, we observed the same results with another GSK-3b
inhibitor (AR) at many phospho-epitopes. However, phosphoryla-
tion on CP13 (Ser202), AT8 (Ser202/Thr205) and AT270 (Thr181)
werenotsignificantlydecreasedatthedoseused.Thesediscrepancies
could be explained by both the high specificity of AR to GSK-3b and
the fact that LiCl is also known to inhibit other kinases
38. Therefore,
the significant decrease of phosphorylation at those phospho-
epitopes observed in LiCl treated samples could be the result of a
cumulative effect of LiCl on GSK-3b and other kinases. The use of
roscovitine in hypothermic SH-SY5Y 3R-tau, reduced hyperpho-
sphorylation at Thr231 and Ser235 epitopes. However, AT270,
(Thr181), CP13 (Ser202), AT8 (Ser202/Thr205), Tau-1 (non-
phosphorylated Ser195/Ser198/Ser199/Ser202) and PHF-1 (Ser-
396/Ser404) epitopes were not significantly decreased. These results
couldbeexplainedbyalesseractivityofCdk5atCP13,AT8andTau-
1 phosphorylation sites
7 since the activation of Cdk5 in neuroblas-
toma cells leads to a smaller increase of phosphorylation at Ser202/
Thr205 than at Thr231 and Ser235 and does not increase tau phos-
phorylationatSer396/Ser404
39.Moreover,increasedactivityofCdk5
observedinamyloidprecursorproteinknockoutmicedoesnotresult
in increased tau phosphorylation at Thr181
40. Therefore, inhibiting
Cdk5 by roscovitine in our hypothermia paradigm reduced tau
hyperphosphorylation at preferred Cdk5 sites such as Thr231 and
Ser235. Altogether, our results show that hypothermia is a suitable
model to assess the specificity of tau kinase inhibitors on tau phos-
phorylation.
One of the main roadblocks for screening and drug testing of tau
phosphorylation inhibitors is that immortal cell lines and adult mice
show low levels of tau phosphorylation. To override this problem, a
largenumber ofbothcellularandanimal models havebeen basedon
the over-expression of mutated human tau to achieve tau hyperpho-
sphorylation
41.However,theuseofhighexpressionlevelsofaggress-
ive tau mutants could lead to pathophysiological mechanisms
Figure 5 | Hypothermia-induced tau hyperphosphorylation is differentially prevented by Cdk5 and GSK-3b inhibitor treatment in SH-SY5Y 3R-Tau.
SH-SY5Y 3R-tau cells were subjected to hypothermia for 2 h and treated with medium alone or medium containing either Cdk5 inhibitor roscovitine
(Rscv)orGSK-3binhibitorAR-A014418.A.ImmunoblotsofSH-SY5Y3R-taucellextractedproteinsusingseveralphospho-tauantibodies(AT8,AT180,
MC-6 and PHF-1). Total tau was probed using a pan tau antibody. B. Immunoblot quantifications. Ratios of phospho-epitope levels over total protein
levels 6SD are represented as a percentage of hypothermic non-treated condition Ctl 30uC (Checkerboard bar). N53 per condition.
www.nature.com/scientificreports
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in the disease. Other studies have induced both hyperphosphory-
lated
42 and abnormally phosphorylated tau
43 through PP2A inhibi-
tion with okadaic acid. However, the high toxicity of okadaic acid,
associated to its pro-apoptotic side effects, limits the relevance of
such models
44. Here, we showed that hypothermia led to easily
detectable tau phosphorylation levels on non-mutated tau expressed
at endogenous levels, which is compatible with tau kinase inhibitors
testing.
In conclusion, we have shown in cells, brain slices and mice, that
hypothermia is a reliable system to model AD-like tau hyperpho-
sphorylation with endogenous wild-type tau protein levels. More-
over, we demonstrated that hypothermia could be used as a
transverse paradigm to evaluate the potency and specificity of tau
kinaseinhibitors.Thisisofparticularimportanceasrecentevidences
implicate pre-fibrillar hyperphosphorylated tau as the toxic species
in AD
45,46, and therefore fuel a regain of interest in tau kinase inhib-
itor development and clinical trials
15.Overall, wepropose that hypo-
thermia and anesthesia-induced hypothermia represent a fast and
useful tool to help in the development and characterization of new
tau phosphorylation modulators from cells to animals.
Methods
Kinase Inhibitors. We used Lithium chloride (LiCl) (Sigma-Aldrich, St-Louis, MO,
USA), AR-A014418 (Enzo life sciences, Farmingdale, NY, USA), and roscovitine
(New England Biolabs, Ipswich, MA, USA).
Animal treatments. 4-month-old C57BL/6 mice of either sex were injected intra-
peritoneally with either sterile water (control group) or sterile water containing
therapeutically relevant dose of 0.6M LiCl for 2 days (once daily at 10 ml/kg), as
previously published
14,47. On the third day, the mice received a last injection and 75
minuteslater,halfthemiceofeachgroupwereanesthetizedbyinjectionofketamine/
xylazine (100/10 mg/kg) in sterile water. The other half received a vehicle injection
(sterile water). Rectal temperature was monitored every 15 minutes after the first
injection until sacrifice, using a rectal probe (Thermalert TH-5; Physitemp, Clifton,
NJ, USA). Mice were sacrificed by decapitation 135 minutes after the last LiCl
injection (i.e. 60minutes after anesthesia). Brainswereremovedand dissected on ice,
and frozen on dry ice. Tissues were kept at 280uC until processing.
Brain slices. 4-month-old C57BL/6 mice were sacrificed by decapitation. Slices were
prepared as previously published
48. Slices were divided into 2 hemibrain slices and
placedintopermeableinserts(TranswellPermeableSupports,Corning,Corning,NY,
USA). After 30 minutes of recovery, transwells were transferred into new 24-well
platescontainingpre-oxygenatedDMEMorDMEMwith20 mMLiCl.Halftheslices
and their contra-lateral counterparts were placed in a 5% CO2 humidified incubator
at30uCforhypothermicconditionsor37uC.After2 h,themediumwasremovedand
the slices were harvested directly in a modified RIPA buffer (see below). Slice
homogenates were kept at 280uC until processing. All animals were handled
according to procedures approved by the Comite ´ de Protection des Animaux under
the guidelines of the Canadian Council on Animal Care.
Cell cultures. Native SH-SY5Y were purchased from American Type Culture
Collection (ATCC #CRL-2266, Manassas, VA, USA) and grown as recommended by
the manufacturer. SH-SY5Y stably overexpressing human 3-repeats (SH-SY5Y
3R-tau) tau cells were a kind gift from Dr Luc Bue ´e (Inserm UMR837, Lille, France)
and subcultured at 37uC, as previously described
49. Cells were treated or not with
either 20 mM LiCl, or 20 mM AR-A014418 as previously published
22,o r2 0mM
roscovitine
50 for 2h. For the duration of the treatment, cells were transferred in a 5%
CO2 humidified incubator at 30uC for hypothermic conditions.
Western blots. Samples were prepared as previously described
19. Proteins were
quantified, separated on SDS-PAGE gels, blottedonto nitrocellulose membranesand
blocked. Membranes were probed with antibodies diluted at the concentration
indicated in Table 1. All antibodies were purchased directly from the provider as
mentioned in Table 1 except for CP13
51, TG-3 and MC-6
52, and PHF-1
53 incubated
with a Horseradish Peroxidase-conjugated secondary antibody (Jackson
Immunoresearch laboratories, West Grove, PA, USA), and revealed by
chemiluminescence in a Fujifilm LAS4000 imaging system (Fujifilm Life Science
USA, Stamford, CT), as previously described
54. Of note, contrary to other antibodies,
Tau-1isdirectedagainstnon-phosphorylatedmultipletauepitopes,andthereforethe
signal decreases when tau is hyperphosphorylated
55. Immunoblot quantifications
were performed by Fujifilm Multigauge software 3.0.
Statistics /Miscellaneous. Statistical analysis was performed with one-way ANOVA
followed by the Dunnet’s post hoc test. For multiple comparisons, one-way ANOVA
followed by the Bonferroni’s post hoc test was performed. *p,0.05, **p,0.01,
***p,0.001, ns: non significant, except otherwise mentioned. GraphPad Prism 5.0
(GraphPad, La Jolla, CA). LibreOffice suite, The GIMP and Mendeley free softwares
were used for data processing, manuscript editing and referencing.
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